Detalhe da pesquisa
1.
Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity.
Mol Pharm
; 11(7): 2442-52, 2014 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24836513
2.
Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax.
Pharm Res
; 31(9): 2503-15, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24633417
3.
A single mutant, A276S of p53, turns the switch to apoptosis.
Mol Pharm
; 10(4): 1350-9, 2013 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23402381
4.
The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria.
Mol Pharm
; 10(10): 3592-602, 2013 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23968395
5.
A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells.
Mol Pharm
; 10(10): 3922-33, 2013 Oct 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23964676
6.
Direct induction of apoptosis using an optimal mitochondrially targeted p53.
Mol Pharm
; 9(5): 1449-58, 2012 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-22380534
7.
Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment.
J Med Chem
; 62(13): 6190-6213, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31259550